Piramal Pharma Limited reported a strong improvement in its financial performance for the second quarter of FY27, with consolidated revenue from operations rising 28% year-on-year (YoY) to \u20b92,617 crore for the quarter ended September 30, 2026. The pharmaceutical company posted a net profit of \u20b95 crore, compared with a net loss of \u20b999 crore in the corresponding quarter of the previous financial year.<\/p>\n\n\n\n
The improvement was supported by growth across its Contract Development and Manufacturing Organisation (CDMO), Complex Hospital Generics (CHG) and Piramal Consumer Healthcare (PCH) businesses. The company also upgraded its full-year FY27 revenue growth outlook following its first-half performance.<\/p>\n\n\n\n
The figures reflect a substantial improvement in operating profitability, although the company\u2019s reported net profit remained modest at \u20b95 crore.<\/p>\n\n\n\n
The company reported growth across all three of its businesses during Q2 FY27.<\/p>\n\n\n\n
The CDMO business reported revenue of \u20b91,424 crore, registering 36% YoY growth compared with \u20b91,044 crore in Q2 FY26. The business was a key contributor to the company\u2019s quarterly revenue growth.<\/p>\n\n\n\n
For the first half of FY27, CDMO revenue reached \u20b92,611 crore, up 28% from \u20b92,041 crore in the corresponding period last year.<\/p>\n\n\n\n
The CHG business recorded revenue of \u20b9849 crore, up 32% YoY from \u20b9644 crore in the year-ago quarter.<\/p>\n\n\n\n
For H1 FY27, revenue from this business rose 24% YoY to \u20b91,592 crore from \u20b91,281 crore. The company highlighted demand for inhalation anaesthesia products in markets outside the United States and the integration of Kenalog among the contributors to business performance.<\/p>\n\n\n\n
The PCH business reported revenue of \u20b9359 crore, reflecting 13% YoY growth from \u20b9319 crore in Q2 FY26.<\/p>\n\n\n\n
For the first half of FY27, revenue increased 14% YoY to \u20b9706 crore from \u20b9621 crore. The company also reported continued growth in its Power Brands and e-commerce channels.<\/p>\n\n\n\n
For the six months ended September 30, 2026, Piramal Pharma reported improvement in revenue and operating profitability.<\/p>\n\n\n\n Despite the return to quarterly profitability, the company continued to report a net loss for the first half of FY27. Its H1 EBITDA margin improved to 13.7%, compared with 9.8% in H1 FY26.<\/p>\n\n\n\n Following its first-half performance, Piramal Pharma revised its FY27 revenue growth outlook to 19%\u201320%<\/strong>, citing business momentum and improved operating performance.<\/p>\n\n\n\n The company said its first-half growth was supported by demand across its businesses, stronger operating leverage and disciplined execution. It also reported that it added 22 new customers and completed 12 regulatory inspections and 110 customer audits during H1 FY27.<\/p>\n\n\n\n The company expects the second half of the financial year to be stronger than the first half, according to its results announcement.<\/p>\n\n\n\n Investors will track whether Piramal Pharma can sustain its revenue momentum and convert the improvement in EBITDA into stronger net profitability over the coming quarters. The company\u2019s performance across CDMO and CHG, capacity utilisation, operating costs and execution of its revised FY27 outlook will remain important indicators.<\/p>\n\n\n\n The return to quarterly profit marks an improvement over the year-ago period, but the relatively small net profit and the H1 net loss mean that sustained profitability will be an important area to monitor.<\/p>\n\n\n\n Piramal Pharma reported 28% YoY revenue growth to \u20b92,617 crore in Q2 FY27 and returned to a net profit of \u20b95 crore from a loss of \u20b999 crore in the corresponding quarter last year. EBITDA rose 72% to \u20b9385 crore, while the company upgraded its FY27 revenue growth outlook to 19%\u201320%.<\/p>\n\n\n\n Although operating performance improved considerably, the company\u2019s ability to sustain growth and strengthen net profitability will be important in the coming quarters.<\/p>\n\n\n\nFinancial metric<\/th> H1 FY27<\/th> YoY change<\/th><\/tr> Revenue from operations<\/td> \u20b94,887 crore<\/td> +23%<\/td><\/tr> Total income<\/td> \u20b95,012 crore<\/td> +22%<\/td><\/tr> EBITDA<\/td> \u20b9669 crore<\/td> +72%<\/td><\/tr> Profit before tax<\/td> \u20b974 crore<\/td> Improved from a loss<\/td><\/tr> Net profit\/loss after tax<\/td> Loss of \u20b964 crore<\/td> Narrowed from a loss of \u20b9202 crore<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n Piramal Pharma Revises FY27 Revenue Growth Outlook<\/h2>\n\n\n\n
What to Watch Next<\/h2>\n\n\n\n
Conclusion<\/h2>\n\n\n\n